RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Ex vivo studies showed that CD19 CAR-T cells efficiently and specifically eliminated RUNX1-mutated BP-CML blasts, affecting both lymphoid and myeloid compartments.